Shopping Cart
- Remove All
Your shopping cart is currently empty
YKL-5-124 TFA is a potent, selective, irreversible and covalent inhibitor of CDK7 (IC50s of 53.5 nM and 9.7 nM for CDK7 and CDK7/Mat1/CycH, respectively).

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 25 mg | $1,670 | 8-10 weeks | |
| 50 mg | $2,180 | 8-10 weeks | |
| 100 mg | $2,800 | 8-10 weeks |
| Description | YKL-5-124 TFA is a potent, selective, irreversible and covalent inhibitor of CDK7 (IC50s of 53.5 nM and 9.7 nM for CDK7 and CDK7/Mat1/CycH, respectively). |
| Targets&IC50 | CDK7:53.5 nM, CDK7-CyclinH-MAT1:9.7 nM, CDK2:1300 nM, CDK9:3020 nM |
| In vitro | In G1- and G2/M-phase cells and a corresponding loss of S-phase cells, YKL-5-124 (0-2000 nM; 72 hours; HAP1 cells) treatment causes a dose-dependent increase . YKL-5-124 (0-2000 nM; 24 hours; HAP1 WT cells) treatment inhibits CDK1 T-loop phosphorylation, and to a lesser extent CDK2 T-loop phosphorylation in a concentration-dependent fashion. |
| Synonyms | YKL-5-124 TFA |
| Molecular Weight | 629.63 |
| Formula | C30H34F3N7O5 |
| Relative Density. | no data available |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 100 mg/mL (158.82 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.